Veltion Therapeutics LLC is stuctured around developing novel approaches for cancer treatment by targeting the Integrated Stress Response and its role in tumor as well as stroma adaptation to stress. Developing novel, potent and specific inhibitors of the ISR pathway with a focus on inhibiting the activity of ATF4, these anti-tumor agents are targeted specifically for pancreatic cancer and fibrosarcoma. Annually, an estimated 57,600 in the U.S. were diagnosed with pancreatic cancer -- an essentially lethal disease with a 5-year survival of less than 10%. Soft tissue sarcoma impacts 13,000 individuals every year, with an overall 5-year survival of 40-60%. Current treatments for both modalities have had modest efficacy.
